Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:33 PM
Ignite Modification Date:
2025-12-24 @ 11:33 PM
NCT ID:
NCT04261556
Eligibility Criteria:
Inclusion Criteria:
* Subjects with clinically definite diagnosis of relapsing remitting MS (RRMS);
* Male or female subjects, 18 to 65 years old;
* Expanded Disability Status Scale (EDSS) score ranging from 0 to 5.5 (included);
* Predominant deficits in either attention/information processing;
* Fluent Italian speakers;
* Normal or corrected-to-normal vision;
* Ability to understand the purpose and risk of the study and provide signed informed consent.
Exclusion Criteria:
* MS patients in different phase of the disease (as primary/secondary progressive MS; benign MS) or Clinical Isolated Syndrome (CIS) patients;
* Exclusive cognitive impairment in different domains (e.g., memory);
* CT/neuromodulation program ongoing or in the preceding 6 months;
* Clinical exacerbations, neuroradiological activity of the disease, modification of EDSS score and disease modifying treatments/steroids during the last 3 months preceding study enrolment;
* Significant medical disorders or other major systemic, psychiatric, neurological disorders or alcohol/substance abuse that could interfere with cognitive functioning;
* Antidepressant/psychoactive drugs in the past 3 months;
* Contraindications to tDCS (intracranial metallic plates, implanted devices, skin disease, superficial injury and fracture or infraction of skull in the stimulation area, epilepsy, pregnancy, etc).
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
65 Years
Study:
NCT04261556
Study Brief:
Protocol Section:
NCT04261556